✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Famitinib is an investigational drug.
There have been 44 clinical trials for Famitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on September 12th 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.
There are forty-five US patents protecting this investigational drug and four hundred and seventy-nine international patents.
Recent Clinical Trials for Famitinib
|Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib||Jiangsu HengRui Medicine Co., Ltd.||Phase 1|
|Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition||Jiangsu HengRui Medicine Co., Ltd.||Phase 1|
|A Study of SHR-1802 in Patients With Advanced Solid Tumor||Jiangsu HengRui Medicine Co., Ltd.||Phase 2|
Top disease conditions for Famitinib
Top clinical trial sponsors for Famitinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Famitinib||See Plans and Pricing||TYK2 inhibitors and uses thereof||Nimbus Lakshimi, Inc. (Cambridge, MA)||See Plans and Pricing|
|Famitinib||See Plans and Pricing||Substituted urea derivatives and pharmaceutical uses thereof||SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)||See Plans and Pricing|
|Famitinib||See Plans and Pricing||Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis||Genentech, Inc. (South San Francisco, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Famitinib||European Patent Office||EP3344624||2035-09-02||See Plans and Pricing|
|Famitinib||Hong Kong||HK1256997||2035-09-02||See Plans and Pricing|
|Famitinib||Japan||JP2018532706||2035-09-02||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|